Chemomab Therapeutics and Scipher Medicine Corporation announced a definitive merger agreement to combine in a stock transaction, with the combined company expected to operate as Scipher Medicine Corporation and trade on Nasdaq under the ticker symbol "SCIP." The combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis by leveraging Scipher’s AI Network Medicine platform, which identified CCL24 as a top-ranked therapeutic target for RA. The Phase 2 RA clinical study is expected to read out in H1 2028. A syndicate of current Scipher investors committed to a new financing totaling approximately $30 million in gross cash proceeds, and the combined company is valued at $150 million before the concurrent private placement. The combined company’s cash balance at closing is expected to fund operations through H2 2028. The combined company will be led by Chief Executive Officer Dr. Reginald Seeto. The companies held a conference call on July 8, 2026 at 8:30 AM ET.